

Global GLP-1 Receptor Agonist Market Forecast 2023-2032 – Market Size, Drivers, Trends, And Competitors

The Business Research Company's GLP-1 Receptor Agonist Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

LONDON, GREATER LONDON, UK, June 1, 2023 /EINPresswire.com/ -- The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business
Research Company

GLP-1 Receptor Agonist Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

The Business Research Company's "GLP-1 Receptor Agonist Global Market Report 2023" is a comprehensive source of information that covers every facet of the [GLP-1 receptor agonist market research](#). As per TBRC's global market forecast, the [GLP-1 receptor agonist market size](#) is predicted to reach a value of \$15.54 billion in 2027, rising at a significant annual growth rate of 4.4% through the forecast period.

“

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032”

*The Business Research
Company*

The rising prevalence of diabetes is expected to propel the [GLP-1 receptor agonist market demand](#) going forward. North America is expected to hold the largest market share. Major players in the market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc.,

Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd.

GLP-1 Receptor Agonist Market Segmentation

- 1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
- 2) By Route Of Administration: Parenteral, Oral
- 3) By End Users: Hospitals, Surgical Clinics, Other Users

Learn More On The Market By Requesting A Free Sample (Includes Graphs And Tables):

<https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp>

This type of receptor agonist is a type of medication that stimulates insulin release at high blood glucose levels and suppresses glucagon secretion under low blood glucose conditions. They are used to treat type 2 diabetes mellitus.

Read More On The Full Global Market Report At:

<https://www.thebusinessresearchcompany.com/report/ghp-1-receptor-agonist-global-market-report>

The Table Of Content For The GLP-1 Receptor Agonist Market Report Include:

1. Executive Summary
2. Market Characteristics
3. GLP-1 Receptor Agonist Market Trends
4. Market Drivers And Restraints
5. GLP-1 Receptor Agonist Market Growth

.....

25. Key Mergers And Acquisitions
26. Competitor Landscape
27. Opportunities And Strategies
28. Conclusions And Recommendations
29. Appendix

Browse Through More Similar Reports By The Business Research Company:

Hemodialysis And Peritoneal Dialysis Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/hemodialysis-and-peritoneal-dialysis-global-market-report>

Blood Collection Devices Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/blood-collection-devices-global-market-report>

Blood Cancer Drugs Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report>

Contact Information

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <https://blog.tbrc.info/>

Healthcare Blog: <https://healthcareresearchreports.com/>

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/637036838>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.